Indoco Remedies' testing facility completes US FDA PAI

The U.S. Food and Drug Administration (U.S. FDA) completed Pre-Approval Inspection (PAI) at the Company's testing facility in Chhatrapati Sambaji Nagar (Aurangabad).

The inspection was carried out from April 08, 2026 to April 10, 2026, and concluded with zero form 483 observations.

Shares of Indoco Remedies Limited was last trading in BSE at Rs. 209.95 as compared to the previous close of Rs. 202.15. The total number of shares traded during the day was 4134 in over 259 trades.

The stock hit an intraday high of Rs. 213.35 and intraday low of 198.90. The net turnover during the day was Rs. 842476.00.

Source : Equity Bulls

Keywords

IndocoRemedies INE873D01024 Pharmaceuticals USFDA PAI